Indolent SM subtype associated with high disease burden
Though patients with ISM have a normal life expectancy, they need more health care visits and medications than the general population.
News
-
-
New clinical trial seeks better treatment for indolent systemic mastocytosis
The HARBOR study will compare elenestinib with a placebo and best supportive care to determine its effectiveness in treating ISM.
-
Case report: Routine colonoscopy helped diagnose a patient with SM
Because SM is a rare disorder, it is sometimes diagnosed incidentally during unrelated procedures.
-
AI predicts systemic mastocytosis risk using electronic health records
AI models analyzed electronic health records to predict which patients may have undiagnosed systemic mastocytosis.
-
Study finds TikTok videos on MCAS are filled with misinformation
The study highlights the risks of relying on social media for medical advice.
-
Keys to SM diagnosis in patients with low circulating KIT D816V
While present in most cases of SM, KIT D816V is not the only diagnostic marker of the disease.
-
Case study provides insights into mast cell leukemia
A recent case report provides insight on the management of mast cell leukemia (MCL), a rare systemic mastocytosis (SM) subtype.
-
Case study: Mast cell leukemia’s rare presentation complicates diagnosis
A recent case study describes how mast cell leukemia can present unusual symptoms that complicate diagnosis.
-
New review analyzes bone disease in systemic mastocytosis
Systemic mastocytosis (SM) can lead to severe osteoporosis, bone pain and fractures, requiring specialized treatment.
-
Case study highlights osteoporosis as a sign of SM
Osteoporosis can be the presenting manifestation of systemic mastocytosis (SM), according to a recent case report.
Learn more about SM
Sign up for the latest news, perspectives, and information about SM.
